Townsend, W, Linch, D. Hodgkin’s lymphoma in adults. Lancet 2012;380(9844):836–847.Google Scholar

Kuruvilla, J, Keating, A, Crump, M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–4217.CrossRefGoogle Scholar

Carella, AM, Congiu, AM, Gaozza, E, Mazza, P, Ricci, P, Visani, G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: an Italian study group report. J Clin Oncol 1988;6(9):1411–1416.Google Scholar

Linch, DC, Winfield, D, Goldstone, AH, Moir, D, Hancock, B, McMillan, A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341(8852):1051–1054.CrossRefGoogle ScholarPubMed

Carella, AM. Role of hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2012;4(1):e2012059.Google Scholar

Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, AM, Haenel, M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359(9323):2065–2071.Google Scholar

Bierman, PJ, Bagin, RG, Jagannath, S, Vose, JM, Spitzer, G, Kessinger, A, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 1993;4(9):767–773.Google Scholar

Crump, M, Smith, AM, Brandwein, J, Couture, F, Sherret, H, Sutton, DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 1993;11(4):704–711.Google Scholar

Reece, DE, Nevill, TJ, Sayegh, A, Spinelli, JJ, Brockington, DA, Barnett, MJ, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant 1999;23(11):1131–1138.CrossRefGoogle ScholarPubMed

Stuart, MJ, Chao, NS, Horning, SJ, Wong, RM, Negrin, RS, Johnston, LJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant 2001;7(10):552–560.Google Scholar

Stewart, DA, Guo, D, Gluck, S, Morris, D, Chaudhry, A, deMetz, C, et al. Double high-dose therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000;26(4):383–388.CrossRefGoogle ScholarPubMed

Moskowitz, CH, Nimer, SD, Zelenetz, AD, Trippett, T, Hedrick, EE, Filippa, DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616–623.Google Scholar

Visani, G, Stefani, PM, Capria, S, Malerba, L, Galieni, P, Gaudio, F, Specchia, G, et al. Bendamustine, etoposide, cytarabine and melphalan (BEEAM) followed by autologous stem cell transplantation produce a 3-year progression-free survival of 75% in heavily pre-treated Hodgkin and non-Hodgkin lymphoma. Blood 2013;122(21):2134.Google Scholar

Andre, M, Henry-Amar, M, Pico, JL, Brice, P, Blaise, D, Kuentz, M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999;17(1):222–229.Google Scholar

Lazarus, HM, Rowlings, PA, Zhang, MJ, Vose, JM, Armitage, JO, Bierman, PJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17(2):534–545.Google Scholar

Hertzberg, M. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT? Hematol Oncol Clin North Am 2014;28(1):123–147.CrossRefGoogle ScholarPubMed

Bains, T, Chen, AI, Lemieux, A, Hayes-Lattin, BM, Leis, JF, Dibb, W, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014;55(3):583–587.Google Scholar

Nieto, Y, Popat, U, Anderlini, P, Valdez, B, Andersson, B, Liu, P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19(3):410–417.Google Scholar

Shafey, M, Duan, Q, Russell, J, Duggan, P, Balogh, A, Stewart, DA. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2012;53(4):596–602.CrossRefGoogle ScholarPubMed

Josting, A, Sieniawski, M, Glossmann, JP, Staak, O, Nogova, L, Peters, N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Ann Oncol 2005;16(8):1359–1365.Google Scholar

Josting, A, Muller, H, Borchmann, P, Baars, JW, Metzner, B, Dohner, H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 2010;28(34):5074–5080.Google Scholar

Fung, HC, Stiff, P, Schriber, J, Toor, A, Smith, E, Rodriguez, T, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007;13(5):594–600.CrossRefGoogle ScholarPubMed

Morschhauser, F, Brice, P, Ferme, C, Divine, M, Salles, G, Bouabdallah, R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26(36):5980–5987.Google Scholar

Biswas, T, Culakova, E, Friedberg, JW, Kelly, JL, Dhakal, S, Liesveld, J, et al. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol 2012;103(3):367–372.Google Scholar

Kahn, S, Flowers, C, Xu, Z, Esiashvili, N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 2011;81(1):175–180.Google Scholar

Poen, JC, Hoppe, RT, Horning, SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996;36(1):3–12.Google Scholar

von Tresckow, B, Muller, H, Eichenauer, DA, Glossmann, JP, Josting, A, Boll, B, et al. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014;55(8):1922–1924.CrossRefGoogle ScholarPubMed

Martinez, C, Canals, C, Sarina, B, Alessandrino, EP, Karakasis, D, Pulsoni, A, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;24(9):2430–2434.CrossRefGoogle ScholarPubMed

Gajewski, JL, Phillips, GL, Sobocinski, KA, Armitage, JO, Gale, RP, Champlin, RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996;14(2):572–578.Google Scholar

Milpied, N, Fielding, AK, Pearce, RM, Ernst, P, Goldstone, AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14(4):1291–1296.CrossRefGoogle ScholarPubMed

Peniket, AJ, Ruiz de Elvira, MC, Taghipour, G, Cordonnier, C, Gluckman, E, de Witte, T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31(8):667–678.Google Scholar

Kharfan-Dabaja, MA, Hamadani, M, Sibai, H, Savani, BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant 2014;49(5):599–606.Google Scholar

Sarina, B, Castagna, L, Farina, L, Patriarca, F, Benedetti, F, Carella, AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115(18):3671–3677.CrossRefGoogle ScholarPubMed

Sureda, A, Robinson, S, Canals, C, Carella, AM, Boogaerts, MA, Caballero, D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(3):455–462.Google Scholar

Peggs, KS, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365(9475):1934–1941.Google Scholar

Anderlini, P, Saliba, R, Acholonu, S, Okoroji, GJ, Donato, M, Giralt, S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35(10):943–951.CrossRefGoogle ScholarPubMed

Sureda, A, Canals, C, Arranz, R, Caballero, D, Ribera, JM, Brune, M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study − a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97(2):310–317.Google Scholar

Anderlini, P, Saliba, RM, Ledesma, C, Chancoco, CM, Alexander, T, Alousi, A, Hosing, CM, et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: Favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Blood 2013;122(21):410.CrossRefGoogle Scholar

Devetten, MP, Hari, PN, Carreras, J, Logan, BR, van Besien, K, Bredeson, CN, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15(1):109–117.Google Scholar

Burroughs, LM, O’Donnell, PV, Sandmaier, BM, Storer, BE, Luznik, L, Symons, HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–1287.Google Scholar

Castagna, L, Bramanti, S, Furst, S, Sarina, B, El-Cheikh, J, Granata, A, et al. Lower relapse and better PFS among chemosensitive patients undergoing allogeneic transplantation by haploidentical compared with HLA-identical donor: results on a cohort of 94 patients with Hodgkin’s lymphoma. Blood 2013;122(21):2144.Google Scholar

Majhail, NS, Weisdorf, DJ, Wagner, JE, Defor, TE, Brunstein, CG, Burns, LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006;107(9):3804–3807.CrossRefGoogle ScholarPubMed

Marcais, A, Porcher, R, Robin, M, Mohty, M, Michalet, M, Blaise, D, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013;98(9):1467–1475.Google Scholar

Peggs, KS, Kayani, I, Edwards, N, Kottaridis, P, Goldstone, AH, Linch, DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 2011;29(8):971–978.Google Scholar

Anderlini, P, Saliba, R, Acholonu, S, Okoroji, GJ, Ledesma, C, Andersson, BS, et al. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma 2012;53(6):1239–1241.Google Scholar

Younes, A, Gopal, AK, Smith, SE, Ansell, SM, Rosenblatt, JD, Savage, KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30(18):2183–2189.CrossRefGoogle ScholarPubMed

Chen, R, Palmer, JM, Tsai, NC, Thomas, SH, Siddiqi, T, Popplewell, L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20(11):1864–1868.Google Scholar

Younes, A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol Oncol Clin North Am 2014;28(1):27–32.Google Scholar

Bartlett, NL, Chen, R, Fanale, MA, Brice, P, Gopal, A, Smith, SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24.CrossRefGoogle ScholarPubMed

Onishi, M, Graf, SA, Holmberg, L, Behnia, S, Shustov, AR, Schiavo, K, et al. Brentuximab vedotin administered to platinum-refractory, transplant-naive Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematol Oncol 2015;33(4):187–91.Google Scholar

Dohner, H, Stilgenbauer, S, Benner, A, Leupolt, E, Krober, A, Bullinger, L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine. 2000;343(26):1910–6. PubMed PMID: 11136261.Google Scholar

Gribben, JG, Zahrieh, D, Stephans, K, Bartlett-Pandite, L, Alyea, EP, Fisher, DC, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389–96. PubMed PMID: 16131571. Pubmed Central PMCID: 1895235.Google Scholar

Jantunen, E, Itala, M, Siitonen, T, Juvonen, E, Koivunen, E, Koistinen, P, et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplantation. 2006;37(12):1093–8. PubMed PMID: 16699533.Google Scholar

Pavletic, ZS, Bierman, PJ, Vose, JM, Bishop, MR, Wu, CD, Pierson, JL, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology/ESMO. 1998;9(9):1023–6. PubMed PMID: 9818078.Google Scholar

Rabinowe, SN, Soiffer, RJ, Gribben, JG, Daley, H, Freedman, AS, Daley, J, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82(4):1366–76. PubMed PMID: 7688995.Google Scholar

Milligan, DW, Fernandes, S, Dasgupta, R, Davies, FE, Matutes, E, Fegan, CD, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105(1):397–404. PubMed PMID: 15117764.Google Scholar

Dreger, P, Stilgenbauer, S, Benner, A, Ritgen, M, Krober, A, Kneba, M, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103(7):2850–8. PubMed PMID: 14670929.Google Scholar

Cheson, BD, Bennett, JM, Grever, M, Kay, N, Keating, MJ, O’Brien, S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990–7. PubMed PMID: 8652811.Google Scholar

Sutton, L, Chevret, S, Tournilhac, O, Divine, M, Leblond, V, Corront, B, et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011;117(23):6109–19. PubMed PMID: 21406717.Google Scholar

Michallet, M, Dreger, P, Sutton, L, Brand, R, Richards, S, van Os, M, et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011;117(5):1516–21. PubMed PMID: 21106985.Google Scholar

de Wreede, LC, Watson, M, van Os, M, Milligan, D, van Gelder, M, Michallet, M, et al. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. American Journal of Hematology. 2014;89(2):174–80. PubMed PMID: 24123244.Google Scholar

Dreger, P, Dohner, H, McClanahan, F, Busch, R, Ritgen, M, Greinix, H, et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood. 2012;119(21):4851–9. PubMed PMID: 22490331.Google Scholar

Michallet, M, Archimbaud, E, Bandini, G, Rowlings, PA, Deeg, HJ, Gahrton, G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Annals of Internal Medicine. 1996;124(3):311–5. PubMed PMID: 8554226.Google Scholar

Pavletic, ZS, Arrowsmith, ER, Bierman, PJ, Goodman, SA, Vose, JM, Tarantolo, SR, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplantation. 2000;25(7):717–22. PubMed PMID: 10745256.Google Scholar

Doney, KC, Chauncey, T, Appelbaum, FR, Seattle Bone Marrow Transplant T. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplantation. 2002;29(10):817–23. PubMed PMID: 12058231.Google Scholar

Toze, CL, Galal, A, Barnett, MJ, Shepherd, JD, Conneally, EA, Hogge, DE, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation. 2005;36(9):825–30. PubMed PMID: 16151430.Google Scholar

Dreger, P, Brand, R, Hansz, J, Milligan, D, Corradini, P, Finke, J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003;17(5):841–8. PubMed PMID: 12750695.Google Scholar

Schetelig, J, van Biezen, A, Brand, R, Caballero, D, Martino, R, Itala, M, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(31):5094–100. PubMed PMID: 18711173.CrossRefGoogle Scholar

Dreger, P, Dohner, H, Ritgen, M, Bottcher, S, Busch, R, Dietrich, S, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438–47. PubMed PMID: 20595516.Google Scholar

Sorror, ML, Storer, BE, Sandmaier, BM, Maris, M, Shizuru, J, Maziarz, R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(30):4912–20. PubMed PMID: 18794548. Pubmed Central PMCID: 2652085.Google Scholar

Brown, JR, Kim, HT, Li, S, Stephans, K, Fisher, DC, Cutler, C, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2006;12(10):1056–64. PubMed PMID: 17084369.CrossRefGoogle ScholarPubMed

Brown, JR, Kim, HT, Armand, P, Cutler, C, Fisher, DC, Ho, V, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27(2):362–9. PubMed PMID: 22955330. Pubmed Central PMCID: 3519975.Google Scholar

Khouri, IF, Wei, W, Korbling, M, Turturro, F, Ahmed, S, Alousi, A, et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014;124(14):2306–12. PubMed PMID: 25145344. Pubmed Central PMCID: 4260365.Google Scholar

Dreger, P, Brand, R, Milligan, D, Corradini, P, Finke, J, Lambertenghi Deliliers, G, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19(6):1029–33. PubMed PMID: 15830011.Google Scholar

Toze, CL, Dalal, CB, Nevill, TJ, Gillan, TL, Abou Mourad, YR, Barnett, MJ, et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. British Journal of Haematology. 2012;158(2):174–85. PubMed PMID: 22640008.CrossRefGoogle Scholar

Sobecks, RM, Leis, JF, Gale, RP, Ahn, KW, Zhu, X, Sabloff, M, et al. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(9):1390–8. PubMed PMID: 24880021. Pubmed Central PMCID: 4174349.Google Scholar

Caballero, D, Garcia-Marco, JA, Martino, R, Mateos, V, Ribera, JM, Sarra, J, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2005;11(21):7757–63. PubMed PMID: 16278397.Google Scholar

Dreger, P, Schnaiter, A, Zenz, T, Bottcher, S, Rossi, M, Paschka, P, et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013;121(16):3284–8. PubMed PMID: 23435461.Google Scholar

Chavez, JC, Kharfan-Dabaja, MA, Kim, J, Yue, B, Dalia, S, Pinilla-Ibarz, J, et al. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leukemia Research. 2014;38(10):1165–72. PubMed PMID: 24889511.Google Scholar

Moreno, C, Villamor, N, Colomer, D, Esteve, J, Martino, R, Nomdedeu, J, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(15):3433–8. PubMed PMID: 15809449.Google Scholar

Khouri, IF, Saliba, RM, Admirand, J, O’Brien, S, Lee, MS, Korbling, M, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. British Journal of Haematology. 2007;137(4):355–63. PubMed PMID: 17456058.Google Scholar

Schetelig, J, Thiede, C, Bornhauser, M, Schwerdtfeger, R, Kiehl, M, Beyer, J, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(14):2747–53. PubMed PMID: 12860954.Google Scholar

Delgado, J, Thomson, K, Russell, N, Ewing, J, Stewart, W, Cook, G, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107(4):1724–30. PubMed PMID: 16239425.Google Scholar

Khouri, IF, Bassett, R, Poindexter, N, O’Brien, S, Bueso-Ramos, CE, Hsu, Y, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011;117(20):4679–88. PubMed PMID: 21455998.Google Scholar

Advani, RH, Buggy, JJ, Sharman, JP, Smith, SM, Boyd, TE, Grant, B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(1):88–94. PubMed PMID: 23045577.Google Scholar

Byrd, JC, Brown, JR, O’Brien, S, Barrientos, JC, Kay, NE, Reddy, NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England Journal of Medicine. 2014;371(3):213–23. PubMed PMID: 24881631.Google Scholar

Byrd, JC, Furman, RR, Coutre, SE, Flinn, IW, Burger, JA, Blum, KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 2013;369(1):32–42. PubMed PMID: 23782158. Pubmed Central PMCID: 3772525.Google Scholar

de Rooij, MF, Kuil, A, Geest, CR, Eldering, E, Chang, BY, Buggy, JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590–4. PubMed PMID: 22279054.Google Scholar

Herman, SE, Gordon, AL, Hertlein, E, Ramanunni, A, Zhang, X, Jaglowski, S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–96. PubMed PMID: 21422473. Pubmed Central PMCID: 3122947.CrossRefGoogle ScholarPubMed

Ponader, S, Chen, SS, Buggy, JJ, Balakrishnan, K, Gandhi, V, Wierda, WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9. PubMed PMID: 22180443.Google Scholar

Cuni, S, Perez-Aciego, P, Perez-Chacon, G, Vargas, JA, Sanchez, A, Martin-Saavedra, FM, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8):1391–400. PubMed PMID: 15175625.Google Scholar

Hoellenriegel, J, Meadows, SA, Sivina, M, Wierda, WG, Kantarjian, H, Keating, MJ, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603–12. PubMed PMID: 21803855.Google Scholar

Longo, PG, Laurenti, L, Gobessi, S, Sica, S, Leone, G, Efremov, DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846–55. PubMed PMID: 17928528.Google Scholar

Brown, JR, Byrd, JC, Coutre, SE, Benson, DM, Flinn, IW, Wagner-Johnston, ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–7. PubMed PMID: 24615777.Google Scholar

Furman, RR, Sharman, JP, Coutre, SE, Cheson, BD, Pagel, JM, Hillmen, P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 2014;370(11):997–1007. PubMed PMID: 24450857.Google Scholar

Seymour, JF, Davids, MS, Pagel, JM, et al., editors. ABT-199 (GDC-0199) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): High Complete Response Rate and Durable Disease Control, American Society of Clinical Oncology Annual Meeting, 2014.Google Scholar

Ma, S, Seymour, JF, Brander, D, et al., editors. ABT-199 (GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase 1b Study. American Society of Clinical Oncology Annual Meeting, 2014.Google Scholar

Cruz, CR, Micklethwaite, KP, Savoldo, B, Ramos, CA, Lam, S, Ku, S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;24:122(17):2965–73. PubMed PMID: 24030379. Pubmed Central PMCID: 3811171.Google Scholar

Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20. PubMed PMID: 22160384. Pubmed Central PMCID: 3327450.Google Scholar

Goede, V, Fischer, K, Busch, R, Engelke, A, Eichhorst, B, Wendtner, CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England Journal of Medicine. 2014;370(12):1101–10. PubMed PMID: 24401022.Google Scholar

Woyach, JA, Johnson, AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015;126(4):471–7. PubMed PMID: 26065659.Google Scholar

Dreger, P, Corradini, P, Kimby, E, Michallet, M, Milligan, D, Schetelig, J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12–7. PubMed PMID: 17109028.Google Scholar

Logan, AC, Zhang, B, Narasimhan, B, Carlton, V, Zheng, J, Moorhead, M, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27(8):1659–65. PubMed PMID: 23419792. Pubmed Central PMCID: 3740398.Google Scholar

Farina, L, Carniti, C, Dodero, A, Vendramin, A, Raganato, A, Spina, F, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica. 2009;94(5):654–62. PubMed PMID: 19377072. Pubmed Central PMCID: 2675677.Google Scholar

Moreno, C, Villamor, N, Colomer, D, Esteve, J, Gine, E, Muntanola, A, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107(11):4563–9. PubMed PMID: 16449533.Google Scholar

Burkhardt, UE, Hainz, U, Stevenson, K, Goldstein, NR, Pasek, M, Naito, M, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. The Journal of Clinical Investigation. 2013;123(9):3756–65. PubMed PMID: 23912587. Pubmed Central PMCID: 3754265.Google Scholar

Rajasagi, M, Shukla, SA, Fritsch, EF, Keskin, DB, DeLuca, D, Carmona, E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–62. PubMed PMID: 24891321.Google Scholar

Richardson, SE, Khan, I, Rawstron, A, Sudak, J, Edwards, N, Verfuerth, S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology. 2013;160(5):640–8. PubMed PMID: 23293871.Google Scholar

Bashey, A, Medina, B, Corringham, S, Pasek, M, Carrier, E, Vrooman, L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–8. PubMed PMID: 18974373. Pubmed Central PMCID: 2644086.Google Scholar

Xerri, L, Chetaille, B, Serriari, N, Attias, C, Guillaume, Y, Arnoulet, C, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Human Pathology. 2008;39(7):1050–8. PubMed PMID: 18479731.Google Scholar

Ansell, SM, Lesokhin, AM, Borrello, I, Halwani, A, Scott, EC, Gutierrez, M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England Journal of Medicine. 2015;372(4):311–9. PubMed PMID: 25482239.Google Scholar

Westin, JR, Chu, F, Zhang, M, Fayad, LE, Kwak, LW, Fowler, N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. The Lancet Oncology. 2014;15(1):69–77. PubMed PMID: 24332512. Pubmed Central PMCID: 3922714.Google Scholar

Armand, P, Nagler, A, Weller, EA, Devine, SM, Avigan, DE, Chen, YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(33):4199–206. PubMed PMID: 24127452.Google Scholar

Treon, SP, Patterson, CJ, Munshi, NC, Anderson, KC. Proceedings of the Seventh International Workshop on Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):181–183.CrossRefGoogle ScholarPubMed

Gertz, MA. Waldenstrom macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88(8):703–711.Google Scholar

Sahota, SS, Forconi, F, Ottensmeier, CH, Provan, D, Oscier, DG, Hamblin, TJ, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002;100(4):1505–1507.Google Scholar

Morton, LM, Wang, SS, Devesa, SS, Hartge, P, Weisenburger, DD, Linet, MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006 Jan 1;107(1):265-276.Google Scholar

Boise, LH, Kaufman, JL, Heffner, LT, Shah, NN, Lechowicz, MJ, Lonial, S, et al. Changing epidemiology and improved survival in patients with Waldenstrom macroglobulinemia: review of surveillance, epidemiology, and end results (SEER) data. Blood 2013;122(21):3135–3135.Google Scholar

Castillo, JJ, Olszewski, AJ, Cronin, AM, Hunter, ZR, Treon, SP. Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood 2014;123(25):3999–4000.Google Scholar

Ciccarelli, BT, Patterson, CJ, Hunter, ZR, Hanzis, C, Ioakimidis, L, Manning, R, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):160–163.Google Scholar

Ansell, SM, Kyle, RA, Reeder, CB, Fonseca, R, Mikhael, JR, Morice, WG, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010;85(9):824–833.Google Scholar

Garcia-Sanz, R, Montoto, S, Torrequebrada, A, de Coca, AG, Petit, J, Sureda, A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001;115(3):575–582.Google Scholar

Michael, AB, Lawes, M, Kamalarajan, M, Huissoon, A, Pratt, G. Cryoglobulinaemia as an acute presentation of Waldenstrom’s macroglobulinaemia. Br J Haematol 2004;124(5):565.Google Scholar

Nobile-Orazio, E, Marmiroli, P, Baldini, L, Spagnol, G, Barbieri, S, Moggio, M, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987;37(9):1506–1514.Google Scholar

Mauro, FR, Foa, R, Cerretti, R, Giannarelli, D, Coluzzi, S, Mandelli, F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95(9):2786–2792.Google Scholar

Treon, SP, Cao, Y, Xu, L, Yang, G, Liu, X, Hunter, ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123(18):2791–2796.Google Scholar

Ocio, EM, Schop, RFJ, Gonzalez, B, Van Wier, SA, Hernandez-Rivas, JM, Gutierrez, NC, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007;136(1):80–86.Google Scholar

Nguyen-Khac, F, Lambert, J, Chapiro, E, Grelier, A, Mould, S, Barin, C, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica 2013;98(4):649–654.CrossRefGoogle Scholar

Sacco, A, Zhang, Y, Maiso, P, Manier, S, Rossi, G, Treon, SP, et al. microRNA aberrations in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):205–207.Google Scholar

Roccaro, AM, Sacco, A, Jia, X, Azab, AK, Maiso, P, Ngo, HT, et al. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010;116(9):1506–1514.Google Scholar

Morel, P, Duhamel, A, Gobbi, P, Dimopoulos, MA, Dhodapkar, MV, McCoy, J, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009;113(18):4163–4170.Google Scholar

Kastritis, E, Zervas, K, Repoussis, P, Michali, E, Katodrytou, E, Zomas, A, et al. Prognostication in young and old patients with Waldenstrom’s macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009;9(1):50–52.Google Scholar

Kyle, RA, Treon, SP, Alexanian, R, Barlogie, B, Bjorkholm, M, Dhodapkar, M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30(2):116–120.Google Scholar

Dimopoulos, M, Kastritis, E, Owen, RG, Kyle, RA, Landgren, O, Morra, E, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Blood 2014;124(9):1404–1411.Google Scholar

Ricci, F, Tedeschi, A, Montillo, M, Morra, E. Therapy-related myeloid neoplasms in chronic lymphocytic leukemia and Waldenstrom’s macroglobulinemia. Mediterr J Hematol Infect Dis 2011;3(1):e2011031.Google Scholar

Cornell, RF, Palmer, J. Adult acute leukemia. Dis Mon 2012;58(4):219–238.Google Scholar

Leblond, V, Johnson, S, Chevret, S, Copplestone, A, Rule, S, Tournilhac, O, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013;31(3):301–307.Google Scholar

Dimopoulos, MA, Alexanian, R, Gika, D, Anagnostopoulos, A, Zervas, C, Zomas, A, et al. Treatment of Waldenstrom’s macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004;45(10):2057–2061.Google Scholar

Gertz, MA, Rue, M, Blood, E, Kaminer, LS, Vesole, DH, Greipp, PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45(10):2047–2055.Google Scholar

Treon, SP, Emmanouilides, C, Kimby, E, Kelliher, A, Preffer, F, Branagan, AR, et al. Extended rituximab therapy in Waldenstrom’s macroglobulinemia. Ann Oncol 2005;16(1):132–138.Google Scholar

Ghobrial, IM, Xie, W, Padmanabhan, S, Badros, A, Rourke, M, Leduc, R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol 2010;85(9):670–674.Google Scholar

Dimopoulos, MA, Garcia-Sanz, R, Gavriatopoulou, M, Morel, P, Kyrtsonis, MC, Michalis, E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013;122(19):3276–3282.Google Scholar

Treon, SP, Soumerai, JD, Branagan, AR, Hunter, ZR, Patterson, CJ, Ioakimidis, L, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452–4457.Google Scholar

Treon, SP, Soumerai, JD, Branagan, AR, Hunter, ZR, Patterson, CJ, Ioakimidis, L, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2009;15(1):355–360.Google Scholar

Rosenthal, AC, Dueck, AC, Gano, K, Ansell, SM, Conley, C, Nowakowski, GS, et al. A Phase 2 Study of lenalidomide, rituximab, cyclophosphamide and dexamethasone (LR-CD) for untreated low grade non-Hodgkin lymphoma requiring therapy: Waldenström’s macroglobulinemia cohort results. Blood 2013;122(21):4352.Google Scholar

Chen, CI, Kouroukis, CT, White, D, Voralia, M, Stadtmauer, E, Stewart, AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(12):1570–1575.Google Scholar

Treon, SP, Hanzis, C, Tripsas, C, Ioakimidis, L, Patterson, CJ, Manning, RJ, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133–135.Google Scholar

Ghobrial, IM, Witzig, TE, Gertz, M, LaPlant, B, Hayman, S, Camoriano, J, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014;89(3):237–242.Google Scholar

Tripsas, CK, Yang, G, Cao, Y, Xu, L, Hunter, Z, Cropper, SJ, et al. A prospective multicenter study of the bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Blood 2013;122(21):251–251.Google Scholar

Anagnostopoulos, A, Dimopoulos, MA, Aleman, A, Weber, D, Alexanian, R, Champlin, R, et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom’s macroglobulinemia. Bone Marrow Transplant 2001;27(10):1027–1029.Google Scholar

Anagnostopoulos, A, Hari, PN, Pérez, WS, Ballen, K, Bashey, A, Bredeson, CN, et al. Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom’s Macroglobulinemia. Biology of Blood and Marrow Transplantation 2006;12(8):845–854.Google Scholar

Gilleece, MH, Pearce, R, Linch, DC, Wilson, M, Towlson, K, Mackinnon, S, et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008;13(2):119–127.Google Scholar

Dhedin, N, Tabrizi, R, Bulabois, PE, Le Gouill, S, Coiteux, V, Dartigeas, C, et al. Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (Wm): update of the French experience in 54 cases. ASH Annual Meeting Abstracts 2007;110(11):3015.Google Scholar

Kyriakou, C, Canals, C, Sibon, D, Cahn, JY, Kazmi, M, Arcese, W, et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28(13):2227–2232.Google Scholar

Dreger, P, Schmitz, N. Autologous stem cell transplantation as part of first-line treatment of Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant 2007;13(5):623–624.Google Scholar

Caravita, T, Siniscalchi, A, Tendas, A, Cupelli, L, Dentamaro, T, Natale, G, et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom’s macroglobulinemia. Bone Marrow Transplant 2009;43(7):587–588.Google Scholar

Munshi, NC, Barlogie, B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom’s macroglobulinemia. Semin Oncol 2003;30(2):282.Google Scholar

Anagnostopoulos, A, Aleman, A, Giralt, S. Autologous and allogeneic stem cell transplantation in Waldenstrom’s macroglobulinemia: review of the literature and future directions. Semin Oncol 2003;30(2):286–290.Google Scholar

Tournilhac, O, Leblond, V, Tabrizi, R, Gressin, R, Senecal, D, Milpied, N, et al. Transplantation in Waldenstrom’s macroglobulinemia: the French experience. Semin Oncol 2003;30(2):291–296.Google Scholar

Stakiw, J, Kim, DH, Kuruvilla, J, Gupta, V, Messner, H, Lipton, JH. Evidence of graft-versus-Waldenstrom’s macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience. Bone Marrow Transplant 2007;40(4):369–372.Google Scholar

Meniane, JC, El-Cheikh, J, Faucher, C, Furst, S, Bouabdallah, R, Blaise, D, et al. Long-term graft-versus-Waldenstrom macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007;40(2):175–177.Google Scholar

Maloney, D. Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant 2008;42(Suppl 1):S35–S36.Google Scholar

Garnier, A, Robin, M, Larosa, F, Golmard, JL, Le Gouill, S, Coiteux, V, et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom’s macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010;95(6):950–955.Google Scholar

Owen, RG, Pratt, G, Auer, RL, Flatley, R, Kyriakou, C, Lunn, MP, et al. Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. Br J Haematol 2014;165(3):316–333.Google Scholar

Marcus, R, Imrie, K, Solal-Celigny, P, Catalano, JV, Dmoszynska, A, Raposo, JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–86.Google Scholar

Hiddemann, W, Kneba, M, Dreyling, M, Schmitz, N, Lengfelder, E, Schmits, R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725−32.Google Scholar

Forstpointner, R, Dreyling, M, Repp, R, Hermann, S, Hanel, A, Metzner, B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064–71.Google Scholar

van Oers, MH, Klasa, R, Marcus, RE, Wolf, M, Kimby, E, Gascoyne, RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295−301.Google Scholar

Salles, G, Seymour, JF, Offner, F, Lopez-Guillermo, A, Belada, D, Xerri, L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.Google Scholar

Morschhauser, F, Radford, J, Van Hoof, A, Vitolo, U, Soubeyran, P, Tilly, H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156–64.Google Scholar

Rummel, MJ, Niederle, N, Maschmeyer, G, Banat, GA, von Grunhagen, U, Losem, C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203−10.Google Scholar

Flinn, IW, van der Jagt, R, Kahl, BS, Wood, P, Hawkins, TE, Macdonald, D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.Google Scholar

Federico, M, Luminari, S, Dondi, A, Tucci, A, Vitolo, U, Rigacci, L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506−13.Google Scholar

Lenz, G, Dreyling, M, Schiegnitz, E, Forstpointner, R, Wandt, H, Freund, M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(9):2667–74.Google Scholar

Deconinck, E, Foussard, C, Milpied, N, Bertrand, P, Michenet, P, Cornillet-LeFebvre, P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105(10):3817−23.CrossRefGoogle ScholarPubMed

Sebban, C, Mounier, N, Brousse, N, Belanger, C, Brice, P, Haioun, C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108(8):2540–4.Google Scholar

Al Khabori, M, de Almeida, JR, Guyatt, GH, Kuruvilla, J, Crump, M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(1):18–28.Google Scholar

Ladetto, M, De Marco, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004−13.Google Scholar

Schaaf, M, Reiser, M, Borchmann, P, Engert, A, Skoetz, N. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev. 2012;1:CD007678.Google Scholar

Wang, B, Ren, C, Zhang, W, Ma, X, Xia, B, Sheng, Z. Intensified therapy followed by autologous stem-cell transplantation versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis. Hematol Oncol. 2013;31(1):29–33.Google Scholar

Montoto, S, Canals, C, Rohatiner, AZ, Taghipour, G, Sureda, A, Schmitz, N, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21(11):2324–31.Google Scholar

Akhtari, M, Bhatt, VR, Tandra, PK, Krishnamurthy, J, Horstman, H, Dreessen, A, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther. 2013 1;14(12):1077–88.Google Scholar

Schouten, HC, Qian, W, Kvaloy, S, Porcellini, A, Hagberg, H, Johnsen, HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918−27.Google Scholar

Le Gouill, S, De Guibert, S, Planche, L, Brice, P, Dupuis, J, Cartron, G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96(8):1128–35.Google Scholar

Vose, JM, Bierman, PJ, Loberiza, FR, Lynch, JC, Bociek, GR, Weisenburger, DD, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008;14(1):36–42.Google Scholar

Gisselbrecht, C, Glass, B, Mounier, N, Singh Gill, D, Linch, DC, Trneny, M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.Google Scholar

Kothari, J, Peggs, KS, Bird, A, Thomson, KJ, Morris, E, Virchis, AE, et al. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol. 2014;165(3):334–40.Google Scholar

Evens, AM, Vanderplas, A, LaCasce, AS, Crosby, AL, Nademanee, AP, Kaminski, MS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013;119(20):3662–71.Google Scholar

Peters, AC, Duan, Q, Russell, JA, Duggan, P, Owen, C, Stewart, DA. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leuk Lymphoma. 2011;52(11):2124–9.Google Scholar

Phipps, C, Gopal, AK, Storer, BE, Cassaday, RD, Press, OW, Till, BG, et al. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Leuk Lymphoma. 2014;17:1–5.Google Scholar

Gopal, AK, Gooley, TA, Rajendran, JG, Pagel, JM, Fisher, DR, Maloney, DG, et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age >/= 60 years with B cell lymphoma. Biol Blood Marrow Transplant. 2014;20(6):770−5.Google Scholar

Decaudin, D, Mounier, N, Tilly, H, Ribrag, V, Ghesquières, H, Bouabdallah, K, et al. 90Y Ibritumomab tiuxetan (zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11(2):212–8.Google Scholar

Brown, JR, Feng, Y, Gribben, JG, Neuberg, D, Fisher, DC, Mauch, P, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13(9):1057–65.Google Scholar

Arcaini, L, Montanari, F, Alessandrino, EP, Tucci, A, Brusamolino, E, Gargantini, L, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008;19(7):1331–5.Google Scholar

Hicks, LK, Woods, A, Buckstein, R, Mangel, J, Pennell, N, Zhang, L, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant. 2009;43(9):701–8.Google Scholar

Brugger, W, Hirsch, J, Grunebach, F, Repp, R, Brossart, P, Vogel, W, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15(11):1691–8.Google Scholar

Morschhauser, F, Recher, C, Milpied, N, Gressin, R, Salles, G, Brice, P, et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol. 2012;23(10):2687–95.Google Scholar

Pettengell, R, Schmitz, N, Gisselbrecht, C, Smith, G, Patton, WN, Metzner, B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2013;31(13):1624–30.Google Scholar

Hari, P, Carreras, J, Zhang, MJ, Gale, RP, Bolwell, BJ, Bredeson, CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14(2):236–45.Google Scholar

Auer, RL, MacDougall, F, Oakervee, HE, Taussig, D, Davies, JK, Syndercombe-Court, D, et al. T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. Br J Haematol. 2012;157(5):580−5.Google Scholar

Shea, T, Johnson, J, Westervelt, P, Farag, S, McCarty, J, Bashey, A, et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant. 2011;17(9):1395–403.Google Scholar

Khouri, IF, Champlin, RE. Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J. 2012;18(5):457–62.Google Scholar

Mortensen, BK, Petersen, SL, Kornblit, B, Andersen, PK, Braendstrup, P, Andersen, NS, et al. Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoeitic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma. Eur J Haematol. 2012;89(2):151–9.Google Scholar

Abou-Nassar, KE, Stevenson, KE, Antin, JH, McDermott, K, Ho, VT, Cutler, CS, et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011;46(12):1503–9.Google Scholar

Freytes, CO, Zhang, MJ, Carreras, J, Burns, LJ, Gale, RP, Isola, L, et al. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012;18(8):1255–64.Google Scholar

Cohen, S, Kiss, T, Lachance, S, Roy, DC, Sauvageau, G, Busque, L, et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant. 2012;18(6):951−7.Google Scholar

Crocchiolo, R, Castagna, L, Furst, S, El-Cheikh, J, Faucher, C, Oudin, C, et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2013;48(2):249–52.Google Scholar

van Besien, K, Loberiza, FR Jr., Bajorunaite, R, Armitage, JO, Bashey, A, Burns, LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–9.Google Scholar

Ingram, W, Devereux, S, Das-Gupta, EP, Russell, NH, Haynes, AP, Byrne, JL, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol. 2008;141(2):235–43.Google Scholar

Tomblyn, MR, Ewell, M, Bredeson, C, Kahl, BS, Goodman, SA, Horowitz, MM, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011;17(7):1051–7.Google Scholar

Delgado, J, Canals, C, Attal, M, Thomson, K, Campos, A, Martino, R, et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia. 2011;25(3):551−5.Google Scholar

Noriega, V, Kaur, H, Devereux, S, Byrne, J, Marcus, R, Haynes, A, et al. Long-term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leuk Res. 2014;38(7):737−43.Google Scholar

Thomson, KJ, Morris, EC, Milligan, D, Parker, AN, Hunter, AE, Cook, G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28(23):3695–700.Google Scholar

Robinson, SP, Canals, C, Luang, JJ, Tilly, H, Crawley, C, Cahn, JY, et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2013;48(11):1409−14.Google Scholar

Harris, NL, Jaffe, ES, Stein, H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361–1392.Google Scholar

Swerdlow, SH, Williams, ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33: 7–20.Google Scholar

van Leeuwen, MT, Turner, JJ, Joske, DJ, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer. 2014;135(9): 2146–2156.Google Scholar

Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89: 3909-3918.Google Scholar

Ohshima, K, Suzumiya, J, Sato, K, Kanda, M, Haraoka, S, Kikuchi, M. B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Lett. 1999;135: 73–81.Google Scholar

Zhou, Y, Wang, H, Fang, W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113: 791–798.Google Scholar

Argatoff, LH, Connors, JM, Klasa, RJ, Horsman, DE, Gascoyne, RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89: 2067–2078.Google Scholar

Bosch, F, Lopez-Guillermo, A, Campo, E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82: 567–575.Google Scholar

Romaguera, JE, Medeiros, LJ, Hagemeister, FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97: 586–591.Google Scholar

Dreyling, M, Hiddemann, W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542–551.Google Scholar

Leitch, HA, Gascoyne, RD, Chhanabhai, M, Voss, NJ, Klasa, R, Connors, JM. Limited-stage mantle-cell lymphoma. Ann Oncol. 2003;14: 1555–1561.Google Scholar

Hoster, E, Dreyling, M, Klapper, W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111: 558–565.Google Scholar

Hoster, E, Klapper, W, Hermine, O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32: 1338–1346.Google Scholar

Royo, C, Salaverria, I, Hartmann, EM, Rosenwald, A, Campo, E, Bea, S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;21: 322–334.Google Scholar

Rosenwald, A, Wright, G, Wiestner, A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3: 185–197.Google Scholar

Jares, P, Campo, E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142: 149–165.Google Scholar

Klapper, W, Hoster, E, Determann, O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2: 103–111.Google Scholar

Cohen, JB, Ruppert, AS, Heerema, NA, et al. Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts. 2012.Google Scholar

Espinet, B, Salaverria, I, Bea, S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49: 439–451.Google Scholar

Dreyling, M, Thieblemont, C, Gallamini, A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24: 857–877.Google Scholar

Herrmann, A, Hoster, E, Zwingers, T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27: 511–518.Google Scholar

Lenz, G, Dreyling, M, Hoster, E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23: 1984–1992.Google Scholar

Tam, CS, Bassett, R, Ledesma, C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113: 4144–4152.Google Scholar

Schulz, H, Bohlius, JF, Trelle, S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99: 706–714.Google Scholar

Lefrere, F, Delmer, A, Suzan, F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16: 587–593.Google Scholar

van ’t Veer, MB, de Jong, D, MacKenzie, M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009;144: 524–530.Google Scholar

Eskelund, CW, Kolstad, A, Jerkeman, M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; July 5. doi: 10.1111/bjh.14241.Google Scholar

Hermine, O, Hoster, E, Walewski, J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016; Aug 6;388(10044):565–75. doi: 10.1016/S0140-6736(16)00739-X.Google Scholar

Chihara, D, Cheah, CY, Westin, JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan;172(1):80–8. doi: 10.1111/bjh.13796.Google Scholar

Bernstein, SH, Epner, E, Unger, JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24: 1587–1593.Google Scholar

Merli, F, Luminari, S, Ilariucci, F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156: 346–353.Google Scholar

Chang, JE, Li, H, Smith, MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123: 1665–1673.Google Scholar

Kenkre, VP, Long, WL, Eickhoff, JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011;52: 1675–1680.Google Scholar

Jantunen, E, Canals, C, Attal, M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23: 166–171.Google Scholar

Rummel, MJ, Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381: 1203–1210.Google Scholar

Flinn, IW, van der Jagt, R, Kahl, BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123: 2944–2952.Google Scholar

Burke, JM, Van der Jagt, RH, Kahl, BS, et al. Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin’s lymphoma or mantle cell lymphoma. ASH Annual Meeting Abstracts. 2012;120: 155.Google Scholar

Cavalli, F, Rooney, B, Pei, L, Van De Velde, H, Robak, T. Investigators aobotL. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). ASCO Meeting Abstracts. 2014;8500.Google Scholar

Visco, C, Finotto, S, Zambello, R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31: 1442–1449.Google Scholar

Kluin-Nelemans, HC, Hoster, E, Hermine, O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367: 520–531.Google Scholar

Martin, P, Smith, M, Till, B. Management of mantle cell lymphoma in the elderly. Best Pract Res Clin Haematol. 2012;25: 221–231.Google Scholar

Weidmann, E, Neumann, A, Fauth, F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22: 1839–1844.Google Scholar

Ghielmini, M, Zucca, E. How I treat mantle cell lymphoma. Blood. 2009;114: 1469–1476.Google Scholar